VISEN PHARMA-B (02561) Surges Over 5% as Commercial Sales of Weizhengao Ramp Up, Marking a Shift to Product Monetization

Stock News07-27

VISEN PHARMA-B (02561) shares climbed more than 5% in the late trading session, reaching HK$20.08, with a turnover of approximately HK$701,400.

This comes after the company's core product, long-acting growth hormone Lonapegsomatropin (branded as Weizhengao), officially received market approval for treating growth hormone deficiency in children and adolescents aged 3 and above, signaling the start of a commercialization cycle for VISEN PHARMA-B.

According to Frost & Sullivan data, the Chinese growth hormone market is expected to reach 28.6 billion yuan by 2030, underpinned by strong long-term growth momentum. In this expanding market, Weizhengao, as the first domestic product combining both "long-acting" and "natural structure" advantages, is poised to carve out a differentiated niche in the high-end segment.

VISEN PHARMA-B is currently pursuing commercialization through an import model in 2026, with plans to achieve technology transfer and localized production by 2028. The company is collaborating with selected CDMO partner WuXi Biologics to advance local manufacturing, further strengthening its production capabilities and supply chain competitiveness.

As commercial sales of Weizhengao gradually increase and contribute to revenue, VISEN PHARMA-B will steadily transition toward a "product monetization" phase, with its valuation center expected to gain stronger fundamental support.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1139443372?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-27 15:50","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1139443372","market":"nz","top_or_hot":-1,"title":"VISEN PHARMA-B (02561) Surges Over 5% as Commercial Sales of Weizhengao Ramp Up, Marking a Shift to Product Monetization","media":"Stock News","content":"<p><b>VISEN PHARMA-B (02561)</b> shares climbed more than 5% in the late trading session, reaching HK$20.08, with a turnover of approximately HK$701,400.<br><br>\nThis comes after the company's core product, long-acting growth hormone Lonapegsomatropin (branded as <b>Weizhengao</b>), officially received market approval for treating growth hormone deficiency in children and adolescents aged 3 and above, signaling the start of a commercialization cycle for <b>VISEN PHARMA-B</b>.<br><br>\nAccording to Frost & Sullivan data, the Chinese growth hormone market is expected to reach 28.6 billion yuan by 2030, underpinned by strong long-term growth momentum. In this expanding market, <b>Weizhengao</b>, as the first domestic product combining both \"long-acting\" and \"natural structure\" advantages, is poised to carve out a differentiated niche in the high-end segment.<br><br>\n<b>VISEN PHARMA-B</b> is currently pursuing commercialization through an import model in 2026, with plans to achieve technology transfer and localized production by 2028. The company is collaborating with selected CDMO partner <b>WuXi Biologics</b> to advance local manufacturing, further strengthening its production capabilities and supply chain competitiveness.<br><br>\nAs commercial sales of <b>Weizhengao</b> gradually increase and contribute to revenue, <b>VISEN PHARMA-B</b> will steadily transition toward a \"product monetization\" phase, with its valuation center expected to gain stronger fundamental support.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>VISEN PHARMA-B (02561) Surges Over 5% as Commercial Sales of Weizhengao Ramp Up, Marking a Shift to Product Monetization</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVISEN PHARMA-B (02561) Surges Over 5% as Commercial Sales of Weizhengao Ramp Up, Marking a Shift to Product Monetization\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-07-27 15:50</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><b>VISEN PHARMA-B (02561)</b> shares climbed more than 5% in the late trading session, reaching HK$20.08, with a turnover of approximately HK$701,400.<br><br>\nThis comes after the company's core product, long-acting growth hormone Lonapegsomatropin (branded as <b>Weizhengao</b>), officially received market approval for treating growth hormone deficiency in children and adolescents aged 3 and above, signaling the start of a commercialization cycle for <b>VISEN PHARMA-B</b>.<br><br>\nAccording to Frost & Sullivan data, the Chinese growth hormone market is expected to reach 28.6 billion yuan by 2030, underpinned by strong long-term growth momentum. In this expanding market, <b>Weizhengao</b>, as the first domestic product combining both \"long-acting\" and \"natural structure\" advantages, is poised to carve out a differentiated niche in the high-end segment.<br><br>\n<b>VISEN PHARMA-B</b> is currently pursuing commercialization through an import model in 2026, with plans to achieve technology transfer and localized production by 2028. The company is collaborating with selected CDMO partner <b>WuXi Biologics</b> to advance local manufacturing, further strengthening its production capabilities and supply chain competitiveness.<br><br>\nAs commercial sales of <b>Weizhengao</b> gradually increase and contribute to revenue, <b>VISEN PHARMA-B</b> will steadily transition toward a \"product monetization\" phase, with its valuation center expected to gain stronger fundamental support.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"KCAI","symbol_name":"KraneShares China Alpha Index ETF","start_time":0,"source_url":"","article_id":"1139443372","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1139443372","pubTimestamp":1785138619,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"VISEN PHARMA-B (02561) shares climbed more than 5% in the late trading session, reaching HK$20.08, with a turnover of approximately HK$701,400. This comes after the company's core product,...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"KCAI":"KraneShares China Alpha Index ETF","BK4588":"碎股","VXUS":"国际股票ETF-Vanguard","BK4585":"ETF&股票定投概念","BK1161":"生物科技","02561":"维昇药业-B"},"translate_title":"威正高商业销售增加，VISEN PHARMA-B (02561) 飙升超过 5%，标志着产品货币化的转变","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02561":1,"KCAI":1,"VXUS":1},"content_text":"VISEN PHARMA-B (02561) shares climbed more than 5% in the late trading session, reaching HK$20.08, with a turnover of approximately HK$701,400.\nThis comes after the company's core product, long-acting growth hormone Lonapegsomatropin (branded as Weizhengao), officially received market approval for treating growth hormone deficiency in children and adolescents aged 3 and above, signaling the start of a commercialization cycle for VISEN PHARMA-B.\nAccording to Frost & Sullivan data, the Chinese growth hormone market is expected to reach 28.6 billion yuan by 2030, underpinned by strong long-term growth momentum. In this expanding market, Weizhengao, as the first domestic product combining both \"long-acting\" and \"natural structure\" advantages, is poised to carve out a differentiated niche in the high-end segment.\nVISEN PHARMA-B is currently pursuing commercialization through an import model in 2026, with plans to achieve technology transfer and localized production by 2028. The company is collaborating with selected CDMO partner WuXi Biologics to advance local manufacturing, further strengthening its production capabilities and supply chain competitiveness.\nAs commercial sales of Weizhengao gradually increase and contribute to revenue, VISEN PHARMA-B will steadily transition toward a \"product monetization\" phase, with its valuation center expected to gain stronger fundamental support.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1139443372","isCrawlerRequest":true}